EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, ARDS: Aridis Pharmaceuticals Inc

23 Oct 2025
LAST:

0.0015

CHANGE:
 0.00		OPEN:
0.0026		HIGH:
0.0026		ASK:
0.0000		VOLUME:
300
CHG(%):
42.31		PREV:
0.0026		LOW:
0.0015		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
23 Oct 250.00260.00260.00150.0015300
22 Oct 250.00260.00260.00260.00261.0K
21 Oct 250.00210.00210.00190.001928.1K
20 Oct 250.00210.00210.00210.0021100
17 Oct 250.00020.00020.00020.0002300
16 Oct 250.00020.00020.00020.000248.1K
15 Oct 250.00030.00030.00020.000235.1K
14 Oct 250.00020.00020.00020.00023.0K
13 Oct 250.00020.00020.00020.0002300
10 Oct 250.00200.00250.00020.0023877.1K

COMPANY PROFILE

Name:Aridis Pharmaceuticals Inc
About:Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
Sector:Healthcare
Industry:Biotechnology
Address:983 University Avenue, Los Gatos, CA, United States, 95032
Website:https://www.aridispharma.com
CUSIP:040334104
CIK:0001614067
ISIN:US0403341045
FIGI:BBG005TNS1Z5

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.0013.3%
MA10:0.0036.4%
MA20:0.0066.7%
MA50:0.000.0%
MA100:0.0087.5%
MA200:0.01420.0%
STO9:54.17
STO14:54.17
RSI14:58.02
WPR14:-45.83
MTM14:0.00
ROC14:6.50 
ATR:0.00 
Week High:0.0073.3%
Week Low:0.00650.0%
Month High:0.0073.3%
Month Low:0.00420.0%
Volatility:1,439.80